1. Home
  2. HBIO vs YI Comparison

HBIO vs YI Comparison

Compare HBIO & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$0.69

Market Cap

33.8M

Sector

Industrials

ML Signal

HOLD

Logo 111 Inc.

YI

111 Inc.

HOLD

Current Price

$2.84

Market Cap

38.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBIO
YI
Founded
1901
2010
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Retail-Drug Stores and Proprietary Stores
Sector
Industrials
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
33.8M
38.1M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
HBIO
YI
Price
$0.69
$2.84
Analyst Decision
Buy
Analyst Count
3
0
Target Price
$2.50
N/A
AVG Volume (30 Days)
555.1K
16.8K
Earning Date
11-06-2025
12-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$87,371,000.00
$1,908,028,152.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$2.48
52 Week High
$2.28
$11.35

Technical Indicators

Market Signals
Indicator
HBIO
YI
Relative Strength Index (RSI) 50.05 37.39
Support Level $0.64 $2.48
Resistance Level $0.80 $3.12
Average True Range (ATR) 0.04 0.25
MACD -0.01 -0.03
Stochastic Oscillator 25.32 29.69

Price Performance

Historical Comparison
HBIO
YI

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.

About YI 111 Inc.

111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.

Share on Social Networks: